Skip to main
GUTS
GUTS logo

GUTS Stock Forecast & Price Target

GUTS Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Fractyl Health Inc is well-positioned for growth, as evidenced by the significant 587% increase in prescriptions for GLP-1 drugs to treat overweight or obesity from 2019 to 2024, highlighting a rising market demand for effective metabolic disease treatments. The company's focus on developing durable, disease-modifying therapies that target the root causes of type 2 diabetes and obesity is supported by the demonstrated effectiveness of GLP-1 PGTx, which offers greater improvements in blood glucose and weight control compared to existing treatments. Furthermore, Fractyl's current manufacturing capabilities are expected to be adequate to support the advancement of its first-in-human Phase 1 trial, with anticipated scalability as the program develops, underscoring the company's potential to capitalize on market opportunities.

Bears say

Fractyl Health Inc. demonstrates potential in improving HbA1c levels among type 2 diabetes patients; however, the financial aspect indicates a troubling trend. The company's increasing cash burn due to the expansion of development and commercial programs raises concerns about its sustainability, despite the possibility of offsetting this cost with milestone revenue from partners. Additionally, the inherent challenge of addressing the gradual loss of β-cell function in T2D patients suggests that achieving long-term therapeutic efficacy may be more complex and resource-intensive than anticipated, further complicating Fractyl's financial outlook.

GUTS has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fractyl Health Inc (GUTS) Forecast

Analysts have given GUTS a Strong Buy based on their latest research and market trends.

According to 4 analysts, GUTS has a Strong Buy consensus rating as of Dec 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fractyl Health Inc (GUTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.